About Cytoplasmic dynein 2 light intermediate chain 1
Cytoplasmic dynein 2 light intermediate chain 1 (DYNC2LI1) is a protein
from Homo sapiens identified by UniProt accession
Q8TCX1, 351 residues long.
MolForge cross-references it against 0 known binders and
31 disease associations.
Target properties
| Protein name | Cytoplasmic dynein 2 light intermediate chain 1 |
|---|
| UniProt accession | Q8TCX1 |
|---|
| Gene | DYNC2LI1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 351 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (31)
Diseases linked to this target (Open Targets).
- Ellis Van Creveld syndrome · score 0.71
- Jeune syndrome · score 0.58
- cholelithiasis · score 0.35
- hemoglobin measurement · score 0.33
- erythrocyte count · score 0.31
- hematocrit · score 0.30
- low density lipoprotein cholesterol measurement · score 0.29
- gallstones · score 0.29
- gallbladder disease · score 0.24
- neurodegenerative disease · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8TCX1-F1 | alphafold | PREDICTED | 85.13 | — |
Amino-acid sequence (351 residues)
MPSETLWEIA KAEVEKRGIN GSEGDGAEIA EKFVFFIGSK NGGKTTIILR CLDRDEPPKP TLALEYTYGR RAKGHNTPKD IAHFWELGGG TSLLDLISIP ITGDTLRTFS LVLVLDLSKP NDLWPTMENL LQATKSHVDK VIMKLGKTNA KAVSEMRQKI WNNMPKDHPD HELIDPFPVP LVIIGSKYDV FQDFESEKRK VICKTLRFVA HYYGASLMFT SKSEALLLKI RGVINQLAFG IDKSKSICVD QNKPLFITAG LDSFGQIGSP PVPENDIGKL HAHSPMELWK KVYEKLFPPK SINTLKDIKD PARDPQYAEN EVDEMRIQKD LELEQYKRSS SKSWKQIELD S
Explore Cytoplasmic dynein 2 light intermediate chain 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets